Fig. 4
Circulating levels of Ly-6Chi cells are higher in fingolimod responder EAE mice. A–C Graphic representation of the clinical course of one representative EAE-Veh (A Ly-6Chicells/total blood cells = 2.26% or Ly-6Chi cells/myeloid cells = 3.15%), one non-responder (B Ly-6Chicells/total blood cells = 2.32%; Ly-6Chicells/myeloid cells = 3.20%) and one responder EAE-FTY720 mouse (C Ly-6Chicells/total blood cells = 4.81% or Ly-6Chicells/myeloid cells = 6.02%). EAE-Veh animals developed a severe clinical course undistinguishable from non-responder EAE-FTY720 mice. D, E Responder EAE-FTY720 mice (N = 3) had a much higher abundance of circulating Ly-6Chicells among the total blood cells (D) or the myeloid component (E) than non-responder EAE-FTY720 mice (N = 15) prior to initiating treatment